Abstract:
The present invention provides compounds of formula (I) wherein A, B, X, Y, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
Abstract:
La presente invencion se refiere a compuestos derivados de tieno[3,2-b]piridina de Formula (I), o una forma de sal del mismo, donde: R1 se selecciona de fenilo y heteroarilo de 5-8 miembros, opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes R1a seleccionados independientemente; R1a se selecciona de ciano, halo, hidroxi, alquilo C1-6, halo-alquilo C1-6 y alcoxi C1-6; R3 se selecciona de hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6 y alquilo C1-6-amino, en donde cada alquilo C1-6, alquenilo C2-6 y alquinilo C2-6 esta opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes R3a seleccionados independientemente, y en cada caso, pueden contener opcionalmente un carbono quiral de configuracion (R) o (S); R3a se selecciona de ciano, halo, hidroxi, oxo, alquilo C1-6, halo-alquilo C1-6, entre otros; R4 se selecciona de hidrogeno, ciano, halo, hidroxi, alquilo C1-6, halo-alquilo C1-6, entre otros; R5 se selecciona de hidrogeno, ciano, halo, hidroxi, alquilo C1-6, halo-alquilo C1-6, entre otros; R6 se selecciona de hidrogeno, halo y alquilo C1-6. Tambien se refiere a composiciones farmaceuticas. Dichos compuestos corresponden son utiles para mejorar el corte y empalme de pre-ARNm en una celula, para tratar o mejorar la disautonomia familiar.
Abstract:
Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.
Abstract:
Described herein is an intronic recognition element for splicing modifier (iREMS) that can be recognized by a small molecule splicing modifier compound of Formula (I) provided herein or a form thereof, wherein W, X, A and B are as defined herein. In one aspect, methods for modifying RNA splicing to modulate the amount of a product of a gene, wherein a precursor RNA transcript transcribed from the gene that contains an intronic REMS is modified utilizing a splicing modifier compound of Formula (I), are described herein. In another aspect, methods for modifying RNA splicing to modulate the amount of an RNA transcript or protein product encoded by a gene, wherein a precursor RNA transcript transcribed from the gene is modified to comprise an intronic REMS utilizing a splicing modifier compound of Formula (I), are described herein.